Pharmaceutical company Allergan Aesthetics, an AbbVie company, has announced Skinvive by Juvéderm has received approval from the US Food and Drug Administration (FDA) to reduce neck lines.
The company shares that this FDA approval marks Skinvive by Juvéderm as the first hyaluronic acid (HA) injectable indicated to reduce the appearance of neck wrinkles and retain hydration, aiming to a rejuvenated neck appearance.
The company shares that the approval was accompanied by a randomised, multi-centre, evaluator-blinded, controlled pivotal clinical study. Out of 105 participants, 74.8% treated in the neck with Skinvive by Juvéderm saw clinically significant improvement on the validated 5-grade photonumeric Allergan Transverse Neck Lines Scale at one month. Additionally, 97 participants had evaluable six-month follow-up data, of whom 66% maintained ≥ 1 point improvement in horizontal neck lines at six months.
Darin Messina, senior vice president and global head of aesthetics research and development at AbbVie, commented, “The submission of Skinvive by Juvéderm to treat neck lines demonstrates our continued focus on developing new indications for comprehensive lower face and neck treatment as part of our market-leading portfolio of products, including Botox Cosmetic and SkinMedica.”